Heeding the pleas of the US government and biopharmaceutical industry, the full US Court of Appeals for the Federal Circuit ruled that Ben Venue Laboratories Inc.'s contract manufacturing of The Medicines Co.'s anticoagulant Angiomax (bivalirudin) was not a commercial sale and thus did not invalidate the company's patents.
The July 11 decision in The Medicines Company v. Hospira clarifies the application of the on-sale bar provision...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?